RESUMEN
The objective of this study was to evaluate unidimensional (mm), bidimensional (mm2), or tridimensional (mL) computed tomography (CT) tumor measurements for ability to discriminate changes in lesion size and predict survival in dogs with nonresectable hepatic carcinoma treated with drug-eluting bead transarterial-chemoembolization (DEB-TACE) and to compare CT response via Response Evaluation Criteria in Solid Tumors 1.1 (mm), World Health Organization (mm2), ellipsoid and spherical volume (mL), and percent necrosis, for their ability to differentiate treatment responders. This was a prospective, single-arm clinical trial. DEB-TACE was performed to varying levels of blood flow stasis in 16 client-owned dogs with nonresectable hepatic carcinoma. Computed tomography imaging responses were assessed and compared to median survival time. Results revealed that initial, follow-up, or changes in unidimensional, bidimensional, or tridimensional tumor measurements were not associated with survival. Larger bidimensional and tridimensional tumor measurements/body weight on initial and follow-up CT were significantly associated with a shorter median survival time [bidimensional (P = 0.04, 0.016) and tridimensional (P = 0.025, 0.015), respectively]. A higher percent necrosis on initial CT was significantly associated with a shorter median survival time (P = 0.038). Ellipsoid volumetric criteria detected treatment response most frequently; however, response classification was not associated with median survival time. Computed tomography bidimensional and tridimensional tumor measurements/body weight before and after DEB-TACE may help to predict median survival time for dogs undergoing DEB-TACE for hepatic carcinoma.
L'objectif de cette étude était d'évaluer les mesures tumorales unidimensionnelles (mm), bidimensionnelles (mm2) ou tridimensionnelles (mL) par tomodensitométrie (CT) pour déterminer la capacité de discriminer les changements de taille des lésions et de prédire la survie chez les chiens atteints d'un carcinome hépatique non-résécable traité avec un médicament par chimioembolisation transartérielle par billes à élution (DEB-TACE) et pour comparer la réponse CT via les critères d'évaluation de la réponse dans les tumeurs solides 1,1 (mm), l'Organisation mondiale de la santé (mm2), le volume ellipsoïde et sphérique (mL) et le pourcentage de nécrose, pour leur capacité à différencier les répondeurs au traitement. Il s'agissait d'un essai clinique prospectif à un seul volet. Le DEB-TACE a été réalisé à différents niveaux de stase du flux sanguin chez 16 chiens appartenant à des clients atteints d'un carcinome hépatique non-résécable. Les réponses d'imagerie par tomodensitométrie ont été évaluées et comparées au temps de survie médian. Les résultats ont révélé que les mesures initiales, de suivi ou les modifications des mesures tumorales unidimensionnelles, bidimensionnelles ou tridimensionnelles n'étaient pas associées à la survie. Des mesures tumorales bidimensionnelles et tridimensionnelles plus grandes/poids corporel sur la CT initiale et de suivi étaient significativement associées à un temps de survie médian plus court [bidimensionnel (P = 0,04, 0,016) et tridimensionnel (P = 0,025, 0,015), respectivement]. Un pourcentage plus élevé de nécrose au scanner initial CT était significativement associé à une durée de survie médiane plus courte (P = 0,038). Les critères volumétriques ellipsoïdes ont détecté la réponse au traitement le plus fréquemment; cependant, la classification des réponses n'était pas associée à la durée médiane de survie. La tomodensitométrie bidimensionnelle et tridimensionnelle des mesures tumorales/poids corporel avant et après DEB-TACE peut aider à prédire la durée médiane de survie des chiens subissant DEB-TACE pour un carcinome hépatique.(Traduit par Docteur Serge Messier).
Asunto(s)
Carcinoma Hepatocelular , Quimioembolización Terapéutica , Enfermedades de los Perros , Neoplasias Hepáticas , Animales , Perros , Carcinoma Hepatocelular/diagnóstico por imagen , Carcinoma Hepatocelular/terapia , Carcinoma Hepatocelular/veterinaria , Quimioembolización Terapéutica/veterinaria , Quimioembolización Terapéutica/métodos , Enfermedades de los Perros/diagnóstico por imagen , Enfermedades de los Perros/terapia , Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/terapia , Neoplasias Hepáticas/veterinaria , Necrosis/terapia , Necrosis/veterinaria , Estudios Prospectivos , Tomografía Computarizada por Rayos X/veterinaria , Resultado del TratamientoRESUMEN
Two dogs with anorexia and rapid weight loss were referred to our hospital due to a right renal mass and several pulmonary nodules. Both dogs underwent needle core biopsy of the mass, followed by transarterial chemoembolisation of the renal mass. A catheter was inserted from the femoral artery and advanced into the right renal artery. A suspension of carboplatin (100 mg/m2 ) and equivalent lipiodol was administered via the inserted multipurpose catheter. Immediately after, under fluoroscopic guidance, pulse injections of small amounts of gelatin particles (diameter 1 mm) dissolved in iohexol were administered until complete embolisation of the renal artery. Histopathologic diagnosis was renal cell carcinoma in both dogs. Clinical signs improved for 134 and 358 days after transarterial chemoembolisation. In addition, postoperative radiographs demonstrated a decrease in the tumour size. The dogs died 215 and 525 days after the initial evaluation, respectively. As a palliative treatment, transarterial chemoembolisation might help reduce the tumour volume and improve the quality of life in dogs with renal cell carcinoma and distant metastases.
Asunto(s)
Carcinoma Hepatocelular , Carcinoma de Células Renales , Quimioembolización Terapéutica , Enfermedades de los Perros , Neoplasias Renales , Neoplasias Hepáticas , Neoplasias Pulmonares , Perros , Animales , Quimioembolización Terapéutica/veterinaria , Carcinoma Hepatocelular/veterinaria , Neoplasias Hepáticas/veterinaria , Carcinoma de Células Renales/terapia , Carcinoma de Células Renales/veterinaria , Cuidados Paliativos , Calidad de Vida , Neoplasias Pulmonares/terapia , Neoplasias Pulmonares/veterinaria , Neoplasias Renales/terapia , Neoplasias Renales/veterinaria , Resultado del Tratamiento , Enfermedades de los Perros/terapiaRESUMEN
BACKGROUND: Chemoembolization is a viable treatment option for patients with nonresectable hepatic carcinoma (HC) and may allow delivery of chemotherapeutic drugs with decreased systemic toxicity. HYPOTHESIS/OBJECTIVE: Compare the serum concentrations of doxorubicin after chemoembolization or IV administration in the same patient. We hypothesized that locoregional delivery may result in increased tumor chemotherapeutic drug concentrations, reflected by decreased measurable serum drug concentrations. Adverse hematological events were hypothesized to be decreased after locoregional delivery. ANIMALS: Seventeen client-owned dogs with incompletely resectable HC. METHODS: Prospective, single-arm clinical trial. Drug-eluting bead transarterial chemoembolization was performed to varying levels of blood flow stasis (NO STASIS, STASIS). Intravenous doxorubicin (IVC) subsequently was administered in selected patients. Systemic exposure was quantified by area under the serum doxorubicin concentration time curve (AUC), maximum serum doxorubicin concentration (Cmax ), and time doxorubicin was last above the limit of quantitation (Tlast ). Nadir test results after treatments were used to evaluate adverse hematological events. RESULTS: Thirteen NO STASIS treatments, 15 STASIS treatments, and 9 IVC treatments were performed. Maximum serum doxorubicin concentration, AUC, and Tlast were significantly lower when comparing NO STASIS or STASIS to IVC treatments. Of the patients with nadir results available, no adverse hematological events were observed after NO STASIS or STASIS treatments. Two patients developed adverse hematological events after IVC treatment. CONCLUSIONS/CLINICAL RELEVANCE: Drug-eluting bead transarterial chemoembolization offers a viable treatment option for patients with incompletely resectable HC with the potential for increased local tumor doxorubicin concentrations, decreased systemic chemotherapeutic exposure, and fewer adverse hematological events.
Asunto(s)
Carcinoma Hepatocelular , Quimioembolización Terapéutica , Enfermedades de los Perros , Neoplasias Hepáticas , Administración Intravenosa/veterinaria , Animales , Antibióticos Antineoplásicos , Carcinoma Hepatocelular/patología , Carcinoma Hepatocelular/veterinaria , Quimioembolización Terapéutica/efectos adversos , Quimioembolización Terapéutica/métodos , Quimioembolización Terapéutica/veterinaria , Enfermedades de los Perros/tratamiento farmacológico , Enfermedades de los Perros/etiología , Perros , Doxorrubicina , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/veterinaria , Estudios Prospectivos , Resultado del TratamientoRESUMEN
Transcatheter arterial embolization (TAE) and transcatheter arterial chemoembolization (TACE) are standard treatments for advanced hepatocellular carcinoma (HCC) and particularly for unresectable tumors or liver metastases in humans. However, reports on TACE used in veterinary medicine are few. This study aimed to evaluate the feasibility and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE). We performed DEB-TACE in four clinically normal dogs and pharmacokinetically compared the results against hepatic arterial infusion (HAI) of cisplatin in two dogs. Drug-eluting beads (DEB) loaded with cisplatin were injected through a microcatheter for selective embolization of the left hepatic artery. After embolization, computed tomography (CT) images and histological examination findings were obtained during a 4-week observation period. Serum platinum concentrations were measured to evaluate cisplatin after each procedure. Biochemical analysis was performed during a 12-week observation period. Embolization was successful in all dogs, and there were no clinically apparent abnormalities. Embolization was confirmed up to 4 weeks after DEB-TACE in two of the four dogs and up to 1 week in the other two dogs using postoperative CT images. Cisplatin was not detected in peripheral veins in all dogs after DEB-TACE, but it was detected in trace amounts after HAI. DEB-TACE using cisplatin was safe and well tolerated by normal dogs. DEB-TACE may be useful in terms of determining systemic toxicity and drug concentration within tumors.
Asunto(s)
Carcinoma Hepatocelular , Quimioembolización Terapéutica , Enfermedades de los Perros , Neoplasias Hepáticas , Preparaciones Farmacéuticas , Animales , Carcinoma Hepatocelular/veterinaria , Quimioembolización Terapéutica/veterinaria , Cisplatino , Enfermedades de los Perros/tratamiento farmacológico , Perros , Doxorrubicina , Arteria Hepática , Neoplasias Hepáticas/veterinaria , Resultado del TratamientoRESUMEN
BACKGROUND: Effective treatment options for nonresectable hepatic carcinoma (HC) in dogs are limited. HYPOTHESIS/OBJECTIVE: Objectives were to report outcomes, complications, and tumor responses via computed tomography (CT) assessment after drug-eluting bead transarterial chemoembolization (DEB-TACE) for nonresectable HC in dogs. The authors hypothesized that major complications would be uncommon and short-term CT assessment would demonstrate stable disease or partial response. ANIMALS: Client-owned dogs (n = 16) with nonresectable HC. METHODS: Prospective, single-arm clinical trial. Drug-eluting bead transarterial chemoembolization was performed to varying levels of blood flow stasis. Computed tomography imaging was compared before and approximately 12 weeks after initial treatment. RESULTS: Drug-eluting bead transarterial chemoembolization was successfully administered in all attempts. Based on percent change in elliptical tumor volume response (mL), stable disease (8/13; 62%) was the most common outcome followed by partial response (3/13; 23%) and progressive disease (2/13; 15%) with a median of 74 days (range, 39-125) after initial treatment. Median tumor volume (mL) after DEB-TACE decreased in volume by 13% (range, 56% decrease to 77% increase). Mild complications consistent with postembolization syndrome occurred after 7/27 (26%) treatments. Major complications occurred after 3/27 (11%) treatments: hepatic abscess/septicemia (2) and cholecystitis/death (1), resulting in treatment-induced death after 2/27 (7%) treatments. Median survival time after treatment was 337 days (range, 22-1061). Dogs with a presenting complaint of weight loss (P = .02) had a significantly shorter median survival time (126 days; range, 46-337) than those dogs without prior history of weight loss (582 days; range, 22-1061). CONCLUSIONS: Drug-eluting bead transarterial chemoembolization for nonresectable HC is a feasible procedure, which promoted stable disease or partial response in 85% of dogs in this study sample.
Asunto(s)
Carcinoma Hepatocelular , Quimioembolización Terapéutica , Enfermedades de los Perros , Neoplasias Hepáticas , Preparaciones Farmacéuticas , Animales , Carcinoma Hepatocelular/veterinaria , Quimioembolización Terapéutica/veterinaria , Enfermedades de los Perros/diagnóstico por imagen , Enfermedades de los Perros/tratamiento farmacológico , Perros , Doxorrubicina/uso terapéutico , Neoplasias Hepáticas/terapia , Neoplasias Hepáticas/veterinaria , Estudios Prospectivos , Resultado del TratamientoRESUMEN
CASE DESCRIPTION: A 16-year-old 6.8-kg (15-lb) castrated male domestic shorthair cat was evaluated because of a 3 × 6-cm mass in the right medial lobe of the liver. CLINICAL FINDINGS: The cat had a history of frequent vomiting and anorexia along with 10% weight loss over the past year. TREATMENT AND OUTCOME: Transcatheter arterial embolization was selected because surgery (standard first-line treatment) was declined and only 1 vessel feeding the tumor was apparent on contrast-enhanced CT. A 4F sheath was placed in the left carotid artery, and a 3.3F guide catheter was advanced into the celiac artery. A 0.014-inch guidewire and 1.7F microcatheter were inserted into the hepatic artery through the guiding catheter and advanced into the feeding vessel. A mixture of polyvinyl alcohol particles and contrast agent was injected for embolization. A hypoechoic area in the tumor was identified on ultrasonography on posttreatment day 6, and necrotic and degenerated cells in the area were identified cytologically. By posttreatment day 71, vomiting had resolved and CT revealed decreased tumor size, but altered attenuation suggested a more solid mass on day 205. No feeding vessel for embolization was found on contrast-enhanced CT, so ultrasonic emulsification to remove the tumor was performed on day 231. No recurrence was seen on contrast-enhanced CT on day 420 or day 721. CLINICAL RELEVANCE: Findings suggested that transcatheter arterial embolization may be suitable for treating hepatic tumors in cats, but alternative approaches are needed in cats, compared with dogs, owing to anatomic differences.
Asunto(s)
Carcinoma Hepatocelular/veterinaria , Enfermedades de los Gatos/cirugía , Quimioembolización Terapéutica/veterinaria , Neoplasias Hepáticas/veterinaria , Animales , Carcinoma Hepatocelular/irrigación sanguínea , Carcinoma Hepatocelular/terapia , Gatos , Quimioembolización Terapéutica/métodos , Medios de Contraste , Yohexol/farmacología , Neoplasias Hepáticas/irrigación sanguínea , Neoplasias Hepáticas/terapia , Masculino , Alcohol Polivinílico/farmacologíaRESUMEN
Nonresectable and metastatic liver tumors are difficult challenges in veterinary patients. As such, these animals traditionally have been treated conservatively and symptomatically. The relatively limited efficacy of routine (intravenous) chemotherapy for macroscopic disease and the cost and potential deleterious side effects associated with radiation therapy have led investigators to evaluate increasingly novel therapeutic modalities. Interventional radiology techniques offer the potential for improved tumor response rates, prolonged survival times, and enhanced quality of life in patients with minimal systemic toxicity risks.
Asunto(s)
Enfermedades de los Gatos/terapia , Quimioembolización Terapéutica/veterinaria , Enfermedades de los Perros/terapia , Neoplasias Hepáticas/veterinaria , Animales , Gatos , Quimioembolización Terapéutica/métodos , Perros , Humanos , Neoplasias Hepáticas/terapia , PronósticoRESUMEN
A 13-year-old, castrated male Siamese cat was presented with a 4-month history of recurrent seizures and bilateral conjunctivitis and rhinitis. Computed tomography of the brain and nose revealed a cystic lesion in the cranial cavity that compressed the brain and invaded the nose. Nasal biopsy revealed a nasal adenocarcinoma. The cat was treated with intermittent antibiotics, phenobarbital, piroxicam, and chemoembolization; it survived for 2 years after diagnosis.
Asunto(s)
Carcinoma Adenoide Quístico/veterinaria , Enfermedades de los Gatos/terapia , Quimioembolización Terapéutica/veterinaria , Terapia Combinada/veterinaria , Neoplasias Nasales/veterinaria , Piroxicam/uso terapéutico , Animales , Carcinoma Adenoide Quístico/tratamiento farmacológico , Carcinoma Adenoide Quístico/terapia , Enfermedades de los Gatos/tratamiento farmacológico , Gatos , Quimioembolización Terapéutica/métodos , Terapia Combinada/métodos , Inhibidores de la Ciclooxigenasa/uso terapéutico , Masculino , Neoplasias Nasales/tratamiento farmacológico , Neoplasias Nasales/terapia , Resultado del TratamientoAsunto(s)
Enfermedades de los Animales/terapia , Embolización Terapéutica/veterinaria , Radiología Intervencionista , Medicina Veterinaria/métodos , Animales , Quimioembolización Terapéutica/métodos , Quimioembolización Terapéutica/veterinaria , Embolización Terapéutica/métodos , Hígado/anomalías , Neoplasias/terapia , Neoplasias/veterinaria , Vena Porta/anomalíasRESUMEN
The term bland arterial embolization refers to catheter-directed delivery of particulate material for the purpose of embolizing selected arteries. This technique is used in humans to treat a number of conditions, including arteriovenous malformations, uterine fibroids, and epistaxis. The term chemoembolization refers to selective intra-arterial delivery of chemotherapeutic agents in conjunction with particulate material for the purpose of embolizing arteries supplying blood to a tumor. Compared with traditional modes of drug delivery, chemoembolization increases local concentration and dwell time of the chemotherapeutic agent, augments tumor ischemia, and minimizes systemic toxic effects. In humans, the technique has shown encouraging results in the treatment of a variety of nonresectable tumors. The present report describes techniques for percutaneous bland arterial embolization and chemoembolization in dogs and goats and results of these techniques in 3 dogs and a goat. Bland arterial embolization was performed in 2 dogs and the goat. The goals of treatment included pain palliation, reduction of tumor growth, and control of hemorrhage, and each animal was considered to have benefited from the procedure on the basis of the preprocedural goals. Chemoembolization was performed in 1 dog for treatment of a nonresectable hepatocellular carcinoma. Unfortunately, this dog did not live long enough to identify any response to treatment. Results for animals studied illustrate the feasibility of bland arterial embolization and chemoembolization in veterinary patients and suggest that embolization may provide an alternative method of treatment for animals with inoperable lesions.